{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:49:27Z","timestamp":1776854967524,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jpsychires.2026.01.041","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:47:40Z","timestamp":1769586460000},"page":"105-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3946-0525","authenticated-orcid":false,"given":"Max","family":"Lydiatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryndis","family":"Grissom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Givens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukanya","family":"Tchombela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-7662","authenticated-orcid":false,"given":"Andjela","family":"Drincic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpsychires.2026.01.041_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","article-title":"Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study","volume":"27","author":"Almalki","year":"2024","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.jpsychires.2026.01.041_bib2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin. Endocrinol."},{"issue":"2","key":"10.1016\/j.jpsychires.2026.01.041_bib3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.jpsychires.2026.01.041_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","article-title":"Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma","volume":"19","author":"Davie","year":"2007","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.01.041_bib5","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EO-21-0038","article-title":"Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?","volume":"2","author":"De Sousa","year":"2022","journal-title":"Endocr. Oncol."},{"issue":"2","key":"10.1016\/j.jpsychires.2026.01.041_bib6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.jpsychires.2026.01.041_bib7","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.jpsychires.2026.01.041_bib8","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.01.041_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf."},{"issue":"8","key":"10.1016\/j.jpsychires.2026.01.041_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin","year":"2023","journal-title":"Arch. Med. Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.01.041_bib11","first-page":"34","article-title":"What makes a screening exam \"good\"? Virtual Mentor","volume":"8","author":"Herman","year":"2006"},{"key":"10.1016\/j.jpsychires.2026.01.041_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.579606","article-title":"Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas","volume":"11","author":"Hinojosa-Amaya","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"10","key":"10.1016\/j.jpsychires.2026.01.041_bib13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamapsychiatry.2023.2206","article-title":"Lifetime incidence of treated mental health disorders and psychotropic drug prescriptions and associated socioeconomic functioning","volume":"80","author":"Kessing","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2026.01.041_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2026.01.041_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.jpsychires.2026.01.041_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mdc3.13128","article-title":"Does the country make a difference in impulse control disorders? A systematic review","volume":"8","author":"Parra-D\u00edaz","year":"2021","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"12","key":"10.1016\/j.jpsychires.2026.01.041_bib17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.jpsychires.2026.01.041_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0028-3886.370452","article-title":"Impulse control disorders with short-term use of cabergoline in macroprolactinomas: a prospective study with a brief review of literature","volume":"71","author":"Sanjan","year":"2023","journal-title":"Neurol. India"},{"issue":"2","key":"10.1016\/j.jpsychires.2026.01.041_bib19","first-page":"249","article-title":"Neuropsychiatric aspects of impulse control disorders","volume":"43","author":"Silva","year":"2020","journal-title":"Psychiatr. Clin."},{"issue":"4","key":"10.1016\/j.jpsychires.2026.01.041_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","article-title":"A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"14","author":"Webster","year":"1996","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.jpsychires.2026.01.041_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.24023","article-title":"Questionnaire for impulsive-compulsive disorders in Parkinson's disease-rating scale","volume":"27","author":"Weintraub","year":"2012","journal-title":"Mov. Disord."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239562600052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239562600052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:13:27Z","timestamp":1774484007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002239562600052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"alternative-id":["S002239562600052X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.01.041","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}